Get the Stockscreener App
2.39
5.53%
-0.14
Tharimmune Inc stock is traded at $2.39, with a volume of 203.32K.
It is down -5.53% in the last 24 hours and down -25.78% over the past month.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
See More
Previous Close:
$2.53
Open:
$2.5
24h Volume:
203.32K
Relative Volume:
0.15
Market Cap:
$83.76M
Revenue:
-
Net Income/Loss:
$-9.32M
P/E Ratio:
-0.188
EPS:
-12.7107
Net Cash Flow:
$-7.30M
1W Performance:
+0.00%
1M Performance:
-25.78%
6M Performance:
+74.45%
1Y Performance:
+9.63%
1-Day Range:
$2.36
$2.64
1-Week Range:
$2.36
$2.75
52-Week Range:
$0.952
$9.08
Tharimmune Inc Stock (THAR) Company Profile
Name
Tharimmune Inc
Sector
Industry
Phone
302-743-2995
Address
1200 ROUTE 22 EAST, BRIDGEWATER
Compare THAR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
2.39 | 88.66M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tharimmune Inc Stock (THAR) Latest News
Tharimmune Appoints Jacob Asbury as Chief Financial Officer - citybiz
Tharimmune Appoints Jacob Asbury as New CFO - TipRanks
Tharimmune appoints Jacob Asbury as chief financial officer - Investing.com
Tharimmune (NASDAQ: THAR) appoints ex‑Clear Street CFO Asbury to guide Canton Coin treasury build‑out - Stock Titan
Why Tharimmune Inc. stock remains a top recommendation2025 Market WrapUp & Free Real-Time Market Sentiment Alerts - Newser
How buybacks impact Tharimmune Inc. stock value2025 EndofYear Setup & Daily Risk Controlled Trade Plans - Newser
How Tharimmune Inc. stock reacts to Fed rate cutsPortfolio Gains Report & Consistent Income Trade Ideas - Newser
Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - The Holland Sentinel
Will Tharimmune Inc. stock benefit from infrastructure spendingInsider Buying & Technical Entry and Exit Tips - Newser
Is Tharimmune Inc. stock attractive for growth ETFsEarnings Recap Summary & High Return Stock Watch Alerts - Newser
Tharimmune (THAR) Stock Analysis Report | Financials & Insights - Benzinga
Can Tharimmune Inc. stock weather global recessionMarket Trend Report & AI Enhanced Trade Execution Alerts - BỘ NỘI VỤ
Reviewing Tharimmune (NASDAQ:THAR) and Ventyx Biosciences (NASDAQ:VTYX) - Defense World
Tharimmune Raises $545 Million in Private Placement to Acquire Canton Coin and Expand Blockchain Adoption - Global Legal Chronicle
What drives Tharimmune Inc stock priceSmall Cap Stock Opportunities & Build Capital Safely - earlytimes.in
Tharimmune Shares Jump After FDA Signals Support for TH104 Modeling Plan - MSN
Crypto Company Creates Bizarre Drug - Futurism
Tharimmune (NASDAQ:THAR) Shares Up 8.9%What's Next? - MarketBeat
Tharimmune Stock Plummets -46% With 9-Day Losing Streak - Trefis
Using Bollinger Bands to evaluate Tharimmune Inc.Gap Up & Expert Curated Trade Setups - newser.com
Will Tharimmune Inc. stock benefit from sector rotationPortfolio Performance Report & Free Accurate Trade Setup Notifications - newser.com
Why analysts upgrade Tharimmune Inc. stockJuly 2025 Selloffs & Free Real-Time Volume Trigger Notifications - newser.com
How resilient is Tharimmune Inc. stock in market downturnsWatch List & Trade Opportunity Analysis Reports - newser.com
Is Tharimmune Inc. stock a buy for dividend growthTrade Exit Summary & Stepwise Swing Trade Plans - newser.com
What insider trading reveals about Tharimmune Inc. stock2025 Momentum Check & Safe Capital Growth Tips - newser.com
Is Tharimmune Inc. stock attractive for retirement portfoliosWeekly Gains Report & Capital Efficiency Focused Strategies - newser.com
Will Tharimmune Inc. stock deliver long term returnsInsider Selling & Verified Momentum Stock Alerts - newser.com
What the charts say about Tharimmune Inc. todayMarket Risk Report & Pattern Based Trade Signal System - newser.com
Will earnings trigger a reversal in Tharimmune Inc.July 2025 Sentiment & Expert Verified Movement Alerts - newser.com
Using data models to predict Tharimmune Inc. stock movementWeekly Investment Summary & Accurate Buy Signal Alerts - newser.com
Will Tharimmune Inc. stock sustain high P E ratiosWall Street Watch & High Accuracy Swing Entry Alerts - newser.com
Is Tharimmune Inc. still worth holding after the dip2025 Short Interest & Risk Adjusted Buy and Sell Alerts - newser.com
[Form 3] Tharimmune, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Tharimmune Shares Drop Premarket Following FDA Feedback on Plan for Lead Clinical Asset - MarketScreener
Tharimmune rises after US FDA backs opioid overdose prevention drug plan - TradingView
Tharimmune stock rises after FDA provides positive feedback on TH104 By Investing.com - Investing.com Nigeria
Tharimmune stock rises after FDA provides positive feedback on TH104 - Investing.com
Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids - Stock Titan
Tharimmune Inc Stock (THAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):